Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of XH-S003 in PNH
NCT07657052Enrolling by invitation
- Sponsor
- Fosun Pharma
- Start
- Aug 2025
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of XH-S003 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Fosun Pharma. Primary endpoint: Incidence and severity of adverse events at 1 year. Started Aug 2025; status: enrolling by invitation.
02
Drugs
XH-S003
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07657052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657052.